Therapeutic Response

EGFR p.T790M status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Osimertinib Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Tagrisso (osimertinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.
Tagrisso (osimertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.